Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Jun 11, 2024
- Pharmaceuticals
- R&D
Maruho Announces Launch of Mitchga Subcutaneous Injection 30mg Vials in Japan
TOKYO, June 11, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Maruho Co., Ltd. (hereafter, Maruho) issued a press release today, regarding the launch of Mitchga® Subcutaneous Injection 30mg Vials (Japanese Accepted Name (JAN): nemolizumab (Genetical Recombination)) in Japan for the treatment of the following diseases only when existing treatment is insufficiently effective: pruritus associated with atopic dermatitis (children aged ≥6 and <13 years) and prurigo nodularis (adults and children aged ≥13 years). Mitchga was originated from Chugai, and has been licensed-out to Maruho in Japan.
Please refer to the link below for details of the press release:
Maruho Launches "Mitchga® Subcutaneous Injection 30mg Vials", an Antibody Treatment for Pruritus Associated with Atopic Dermatitis (Pediatric) and Prurigo Nodularis in Japan
